(688526)"Wuhan Keqian Biology Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688526 · · 14 pages · Chinese
Summary by 6ix AI
The report indicates significant declines in revenue and profit compared to the same period last year, attributed to market conditions affecting sales. The company also highlights its ongoing research and development efforts, including the acquisition of new veterinary drug registrations.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Wuhan Keqian Biology Co. Ltd. on 6ix
Earlier from Wuhan Keqian Biology
- Indicative Announcement on Expiration and Termination of the Shareholders' Concerted Action Agreement and the Company Having No Actual Controller
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on the 2026 Semi-annual Performance Briefing
- Announcement on Expiration of the Lock-up Period and Satisfaction of Certain Unlocking Conditions under the 2025 Employee Stock Ownership Plan
- Voluntary Disclosure Announcement on the Proposed Signing of a Cooperative R&D Agreement with Huazhong Agricultural University and the Related Party Transaction
Later from Wuhan Keqian Biology
- (688526)"Wuhan Keqian Biology Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (688526)"Wuhan Keqian Biology Co., Ltd."Announcement on Resignation of Independent Directors Due to Completion of Six Consecutive Years of Service
Follow Wuhan Keqian Biology into a list and get an email when it puts out news.
Follow Wuhan Keqian Biology